{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T23:26:45Z","timestamp":1747178805720,"version":"3.40.5"},"reference-count":130,"publisher":"Informa UK Limited","issue":"14","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2024,9,21]]},"DOI":"10.1080\/14656566.2024.2408376","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T06:23:57Z","timestamp":1727159037000},"page":"1887-1902","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Advances in pharmacotherapy for heart failure and reduced ejection fraction: what\u2019s new in 2024?"],"prefix":"10.1080","volume":"25","author":[{"given":"Zahra","family":"Ismail","sequence":"first","affiliation":[{"name":"St. George\u2019s, University of London, Cranmer Terrace, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5050-6793","authenticated-orcid":false,"given":"Maryam","family":"Aboughdir","sequence":"additional","affiliation":[{"name":"Royal Free London NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bea","family":"Duric","sequence":"additional","affiliation":[{"name":"GKT School of Medical Education, King\u2019s College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahil","family":"Kakar","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham; Queen Elizabeth Hospital, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey Shi Kai","family":"Chan","sequence":"additional","affiliation":[{"name":"Heart Failure and Structural Heart Disease Unit, Cardiovascular Analytics Group, United Kingdom-China Collaboration, Hong Kong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmin","family":"Bayatpoor","sequence":"additional","affiliation":[{"name":"Manchester Royal Infirmary, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5507-5841","authenticated-orcid":false,"given":"Amer","family":"Harky","sequence":"additional","affiliation":[{"name":"Liverpool Heart and Chest Hospital, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"e_1_3_5_3_1","first-page":"e895","article-title":"AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the american college of Cardiology\/american heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the american college of Cardiology\/american heart association joint committee on clinical practice guidelines. Circulation. 2022;145:e895\u2013e1032.","journal-title":"Circulation"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-023-03337-1"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2023.07.006"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac013"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.13429"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2023.101634"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab670"},{"key":"e_1_3_5_10_1","unstructured":"Strategy for an early simultaneous introduction of four-pillars of heart failure therapy: results from a single center experience |. American journal of cardiovascular drugs [Internet]. [cited 2024 Sep 2]. Available from: https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00660-6#Sec6"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2024.02.020"},{"key":"e_1_3_5_12_1","unstructured":"Buttar C Alai H Matanes FN et al. Full decongestion in acute heart failure therapy. The American journal of the medical sciences [Internet]. 2024 Jul 10. p. S0002962924012734. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962924012734"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13677"},{"key":"e_1_3_5_14_1","unstructured":"Vyas A Onteddu N. Vericiguat. StatPearls Publishing; Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK574528\/"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411826"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/03000605231159333"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-024-10412-y"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd10090388"},{"key":"e_1_3_5_19_1","unstructured":"Paul Wayne Armstrong MD FACC. Bavry AA. MDMPH FACC. Vericiguat global study in subjects with heart failure with reduced ejection fraction - VICTORIA [internet]. 2024. Available from: https:\/\/www.acc.org\/Latest-in-Cardiology\/Clinical-Trials\/2020\/03\/26\/19\/43\/VICTORIA"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2511"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2836"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14802"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac389"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-024-00652-6"},{"key":"e_1_3_5_25_1","unstructured":"Stehlik J. The effect of vericiguat on peripheral vascular function patient health status and inflammation. NCT05420012. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05420012"},{"key":"e_1_3_5_26_1","unstructured":"Bayer. A study to learn how well the drug vericiguat works and how safe it is under real world conditions in Indian participants after worsening of a long-term heart condition in which the left side of the heart does not pump blood as well as it should (chronic heart failure with reduced ejection fraction). Available from: https:\/\/clinicaltrials.gov\/study\/NCT05658458"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2020.08.008"},{"key":"e_1_3_5_28_1","unstructured":"Diala N Kerndt CC Patel P et al. Sacubitril-Valsartan. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507904\/"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-023-00323-8"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2014-306775"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2020.06.020"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.01.027"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-021-00501-6"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41540-017-0013-4"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2020.25"},{"key":"e_1_3_5_36_1","unstructured":"Gautam Sen. Sacubitril\/Valsartan: where are we now? Available from: https:\/\/www.britishcardiovascularsociety.org\/resources\/editorials\/articles\/sacubitrilvalsartan-where-are-we-now"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.15209"},{"key":"e_1_3_5_38_1","unstructured":"Pulmonary REsistance modification under treatment with Sacubitril\/valsartaN in paTients with heart failure with reduced ejection fraction [internet]. Available from: https:\/\/www.trialx.com\/clinical-trials\/listings\/260309\/pulmonary-resistance-modification-under-treatment-with-sacubitrilvalsartan-in-patients-with-heart-failure-with-reduced-ejection-fraction\/"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.243"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1906"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i610"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30412-6"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00424-014-1619-7"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00102-5"},{"key":"e_1_3_5_48_1","unstructured":"National Institute for Health and Care Excellence. Heart failure - chronic: SGLT2 inhibitors [Internet]. 2024. Available from: https:\/\/cks.nice.org.uk\/topics\/heart-failure-chronic\/prescribing-information\/sglt-2-inhibitors\/"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0839-8"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-018-4670-7"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0330"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4509-7"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4134-x"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12336"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-13-28"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.600866"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.07.018"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1159\/000438864"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1227166"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0816-2"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1473"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-017-6734-1"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0790-0"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.5334\/gh.1258"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.60919"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-0236"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2023.05.002"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1373314"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz258"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3024"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-0764"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)00185-X"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.10260"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14862"},{"key":"e_1_3_5_75_1","unstructured":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of Major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus | circulation [Internet]. [cited 2024 Sep 2]. Available from: https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.118.038868"},{"key":"e_1_3_5_76_1","unstructured":"Cardiovascular outcomes with SGLT2 inhibitors versus DPP4 inhibitors and GLP-1 receptor agonists in patients with heart failure with reduced and preserved ejection fraction - PubMed [Internet]. [cited 2024 Sep 2]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/36899387\/"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41430-020-0558-y"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx235"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2017.0175"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020545"},{"key":"e_1_3_5_81_1","unstructured":"VItamiN D treatIng chronic heArT failure (the effect of vitamin D supplementation in patients with heart failure) (VINDICATE2). University of Leeds. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03416361"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01875-8"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1177\/2333794X221110860"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2014.10.007"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-009-0092-3"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32339-4"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02083-9"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2810"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304968"},{"key":"e_1_3_5_91_1","doi-asserted-by":"crossref","unstructured":"Effects and safety of oral iron for heart failure with iron deficiency: a systematic review and Meta\u2010analysis with trial sequential analysis - tan - 2022 - cardiovascular therapeutics - wiley online library [Internet]. [cited 2024 Sep 2]. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2022\/6442122","DOI":"10.1155\/2022\/6442122"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106345"},{"key":"e_1_3_5_93_1","doi-asserted-by":"crossref","unstructured":"Iron deficiency anemia: the impact of intravenous iron replacement treatment on health care costs | blood | american society of hematology [Internet]. [cited 2024 Sep 2]. Available from: https:\/\/ashpublications.org\/blood\/article\/142\/Supplement%201\/3697\/503125\/Iron-Deficiency-Anemia-The-Impact-of-Intravenous","DOI":"10.1182\/blood-2023-187608"},{"key":"e_1_3_5_94_1","unstructured":"Omecamtiv mecarbil: a novel mechanistic and therapeutic approach to chronic heart failure management | cureus [Internet]. [cited 2024 Sep 2]. Available from: https:\/\/www.cureus.com\/articles\/47520-omecamtiv-mecarbil-a-novel-mechanistic-and-therapeutic-approach-to-chronic-heart-failure-management#!\/"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32049-9"},{"key":"e_1_3_5_96_1","unstructured":"Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: the ATOMIC-AHF study - ScienceDirect [Internet]. [cited 2024 Sep 2]. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S073510971600351X?via%3Dihub"},{"key":"e_1_3_5_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2023.09.005"},{"key":"e_1_3_5_98_1","unstructured":"Ivabradine - StatPearls - NCBI Bookshelf [Internet]. [cited 2024 Sep 2]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507783\/"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.01.020"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61170-8"},{"key":"e_1_3_5_101_1","unstructured":"Overview | chronic heart failure in adults: diagnosis and management | guidance | NICE [Internet]. NICE; 2018 [cited 2024 Sep 2]. Available from: https:\/\/www.nice.org.uk\/guidance\/ng106"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad613"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad617"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203094"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac689"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10184207"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.1111\/anae.14038"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2019.11.013"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.02.009"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.02.012"},{"key":"e_1_3_5_113_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartjsupp\/suad055"},{"key":"e_1_3_5_114_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01659-1"},{"key":"e_1_3_5_115_1","doi-asserted-by":"crossref","unstructured":"Pascual\u2010Figal D N\u00fa\u00f1ez Villota J P\u00e9rez\u2010Mart\u00ednez MT et al. Colchicine in acute heart failure: rationale and design of a randomized double\u2010blind placebo\u2010controlled trial (COLICA). European J of heart fail [Internet]. 2024. p. ejhf.3300. Available from https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ejhf.3300","DOI":"10.1002\/ejhf.3300"},{"key":"e_1_3_5_116_1","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S460641"},{"key":"e_1_3_5_117_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-024-02026-5"},{"key":"e_1_3_5_118_1","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14930"},{"key":"e_1_3_5_119_1","unstructured":"Cost-effectiveness of comprehensive quadruple therapy for heart failure with reduced ejection fraction - ScienceDirect [Internet]. [cited 2024 Sep 2]. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S221317792300032X"},{"key":"e_1_3_5_120_1","unstructured":"The economics of heart failure care - ScienceDirect [internet]. [cited 2024 Sep 2]. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0033062024000100?via%3Dihub"},{"key":"e_1_3_5_121_1","unstructured":"Novartis pharmaceuticals. A proof of concept and dose-finding study of XXB750 in patients with heart failure [Internet]. 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06142383?tab=results"},{"key":"e_1_3_5_122_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115772"},{"key":"e_1_3_5_123_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-019-0218-x"},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.495"},{"key":"e_1_3_5_125_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2090"},{"key":"e_1_3_5_126_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14349-2"},{"key":"e_1_3_5_127_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa791"},{"key":"e_1_3_5_128_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa898"},{"key":"e_1_3_5_129_1","unstructured":"Uric acid levels and heart failure: a mendelian randomization study - nutrition metabolism and cardiovascular diseases [Internet]. [cited 2024 Jul 28]. Available from: https:\/\/www.nmcd-journal.com\/article\/S0939-4753(23)00517-3\/abstract"},{"key":"e_1_3_5_130_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.24297"},{"key":"e_1_3_5_131_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-4859-4"},{"key":"e_1_3_5_132_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13101"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2024.2408376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T10:59:30Z","timestamp":1729076370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2024.2408376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,21]]},"references-count":130,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024,9,21]]}},"alternative-id":["10.1080\/14656566.2024.2408376"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2024.2408376","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"type":"print","value":"1465-6566"},{"type":"electronic","value":"1744-7666"}],"subject":[],"published":{"date-parts":[[2024,9,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-08-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}